Use: Labeled indications
- Hypertension, to lower blood pressure.
- Angina Pectoris.
- Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically…
Full indications and usage US FDA label
1 IND ICATIONS AND USAGE LOPRESSOR is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Angina Pectoris. (1.2) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients.
(1.3) 1.1 Hypertension LOPRESSOR is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. LOPRESSOR may be administered with other antihypertensive agents. 1.2 Angina Pectoris LOPRESSOR is indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Myocardial Infarction Lopressor tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol.
Contraindications
4 CONTRAINDICATIONS LOPRESSOR is contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, systolic blood pressure <100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product. Known hypersensitivity to product components. (4) Severe bradycardia: Greater than first degree heart block, or sick sinus syndrome without a pacemaker. (4) Cardiogenic shock or decompensated heart failure. (4)
US FDA labelDosing: Adult
- Administer once daily with food or after a meal. Titrate at weekly or longer intervals as needed and tolerated. (2) Hypertension: Recommended starting dosage is 100 mg daily, in single or divided doses. (2.1)
- Angina Pectoris: Recommended starting dosage is 100 mg daily, given as two divided doses. (2.2)
- Myocardial Infarction: The starting dosage depends upon tolerance of intravenous metoprolol, see full prescribing information. (2.3)
2.1 Hypertension
2.1 Hypertension Individualize the dosage of Lopressor tablets. Lopressor tablets should be taken with or immediately following meals. The usual initial dosage is 100 mg daily in single or divided doses. Adjust dosage at weekly (or longer) intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after 1 week of therapy.
The effective dosage range of Lopressor tablets is 100 mg to 450 mg per day. Dosages above 450 mg per day have not been studied. While once-daily dosing can maintain a reduction in blood pressure throughout the day, lower doses (especially 100 mg) may not maintain a full effect at the end of the 24-hour period. Larger or more frequent daily doses may be required.
Measure blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the day.
2.2 Angina Pectoris
2.2 Angina Pectoris The dosage of Lopressor tablets should be individualized. Lopressor tablets should be taken with or immediately following meals. The usual initial dosage is 100 mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until optimum clinical response has been obtained or there is a pronounced slowing of the heart rate.
The effective dosage range of Lopressor tablets is 100 to 400 mg per day. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, reduce the dosage gradually over a period of 1 - 2 weeks [see Warnings and Precautions (5.1)].
2.3 Myocardial Infarction
2.3 Myocardial Infarction See prescribing information of intravenous metoprolol for dosage instructions for intravenous therapy. In patients who tolerate the full intravenous dose, initiate Lopressor tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for 48 hours. In the case of intolerance, reduce dose to 25 mg and administer for 48 hours.
Titrate, based on tolerability, to a maintenance dosage of 100 mg twice daily. Continue therapy for at least 3 months. Although the efficacy of Lopressor beyond 3 months has not been conclusively established, data from studies with other beta-blockers suggest that treatment should be continued for 1 to 3 years.
Dosing: Altered kidney function
8.7 Renal Impairment The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. No reduction in dosage is needed in patients with chronic renal failure [see Clinical Pharmacology (12.3)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment No studies have been performed with LOPRESSOR in patients with hepatic impairment. Because LOPRESSOR is metabolized by the liver, metoprolol blood levels are likely to increase substantially with poor hepatic function. Therefore, initiate therapy at doses lower than those recommended for a given indication; and increase doses gradually in patients with impaired hepatic function.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of LOPRESSOR have not been established in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of LOPRESSOR in hypertension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience in hypertensive patients has not identified differences in responses between elderly and younger patients.
In worldwide clinical trials of Lopressor in myocardial infarction, where approximately 478 patients were over 65years of age (0 over 75 years of age), no age-related differences in safety and effectiveness were found. Other reported clinical experience in myocardial infarction has not identified differences in response between the elderly and younger patients.
In general, use a low initial starting dose in elderly patients given their greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Dosage forms
Philippines
- Tablet: 50 mg, 100 mg
- Film-coated tablet: 50 mg, 100 mg
- Controlled-release tablet: 47.5 mg, 95 mg
- Extended-release tablet: 47.5 mg, 95 mg
- Metoprolol tartrate): 23.75 mg Controlled-Release Tablet (equivalent to 25 mg, 95 mg Extended Release Tablet (equivalent to 100 mg
- Solution for i.v. injection: 1 mg/mL
Registered products in the Philippines
111 products registered with the Food and Drug Administration (FDA) Philippines list Metoprolol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products111
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AngimetMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1554-07 | Mar 30, 2029 | |
AngimetMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1553-04 | May 5, 2029 | |
ArtolMetoprolol Tartrate | 100 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | 1789152 FDA-5000017891522 | Jun 5, 2030 | |
ArtolMetoprolol Tartrate | 50 mg TabletAlu Clear/PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-14561-03 | Oct 13, 2030 | |
B-BlocMetoprolol (as tartrate) | 100 mg Film-Coated TabletClear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Metz Pharmaceuticals, Inc.Trader: Vitalink Health Products, Inc. | DRP-4215-01 | Nov 23, 2029 | |
B-BlocMetoprolol Tartrate | 50 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Metz Pharmaceuticals, Inc.Trader: VItalink Health Products, Inc. | DRP-3073-02 | Sep 30, 2028 | |
BetacorMetoprolol Tartrate | 100mg TabletBlister pack x 10's Box of 100's; Blister pack x 20's Box of 100's | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-11914 | May 20, 2029 | |
BetacorMetoprolol Tartrate | 50 mg TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-800 | Mar 22, 2028 | |
BetalocMetoprolol Tartrate | 100 mg TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 105's) | RxVAT-exempt | AstraZeneca Pharmaceutical Company Ltd.China | Importer: AstraZeneca Pharmaceuticals (Phils.), Inc. | DR-X1812 | Apr 2, 2027 | |
BetalocMetoprolol Tartrate | 50 mg TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | AstraZeneca Pharmaceutical Company Ltd.China | Importer: AstraZeneca Pharmaceuticals (Phils.), Inc. | DR-X1848 | Mar 12, 2037 | |
BetavascMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DR-XY44603 | Jun 26, 2030 | |
BetavascMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DR-XY44262 | Mar 19, 2030 | |
BetazokMetoprolol Succinate | 23.75 mg Controlled-Release Tablet (equivalent to 25 mg Metoprolol Tartrate)Alu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | AstraZeneca ABSweden | Importer: AstraZeneca Pharmaceuticals (Phils.), Inc. | DRP-10241 | Oct 8, 2028 | |
BetazokMetoprolol succinate | 47.5 mg Controlled-Release TabletAlu/PVC Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Astrazeneca ABSweden | AstraZeneca Pharmaceuticals (Phils.), Inc. | DR-XY49671 | Mar 12, 2031 | |
BetazokMetoprolol Succinate (equivalent to 100 mg Metoprolol Tartrate) | 95 mg Controlled Release TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 105's) | RxVAT-exempt | AstraZeneca ABSweden | Importer: AstraZeneca Pharmaceuticals (Phils.), Inc. | DR-XY12973 | Sep 24, 2029 | |
BetrolMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Better Options Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1554-06 | Mar 30, 2029 | |
CardioselMetoprolol Tartrate | 100 mg TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | UNILAB, Inc. | DRP-2846-01 | Jan 11, 2028 | |
CardioselMetoprolol Tartrate | 50 mg TabletBlister Pack x 20's Box of 100's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | UNILAB, INC. | DRP-2887-01 | Jan 7, 2028 | |
Cardiosel-ODMetoprolol (as Succinate) | 47.5 mg Extended-Release TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | UNILAB, Inc. | DR-XY39230 | Mar 29, 2031 | |
CardiostatMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DR-XY40254 | Nov 3, 2031 | |
CardiostatMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: One Pharma Marketing Inc. | DR-XY37399 | Jan 25, 2030 | |
CardiotabMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Eliset Pharmaceutical, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1554 | Mar 30, 2029 | |
CardiotabMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Eliset Pharmaceutical, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1553 | May 5, 2029 | |
CarditecMetoprolol Tartrate | 50 mg TabletAlu/PVC Blister Pack x 20's Box of 100's | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | Terramedic, Inc. | DRP-800-01 | Mar 22, 2028 | |
DocmetMetoprolol Tartrate | 100 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | Trader: Docteur's Choice Corporation | DRP-13337 | Jan 30, 2028 | |
DocmetMetoprolol Tartrate | 50 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | Trader: Docteur's Choice Corporation | DRP-12368 | Jul 26, 2027 | |
FredmetMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-17758 | Feb 27, 2031 | |
FredmetMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Enterprises Inc | DRP-17759 | Feb 27, 2031 | |
GolmetMetoprolol Tartrate | 100 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's m Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | Trader: Golden Dale Pharma Corp. | DRP-13315 | Jan 26, 2028 | |
GolmetMetoprolol Tartrate | 50 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | Trader: Golden Dale Pharma Corp. | DRP-12381 | Jul 28, 2027 | |
HypetorMetoprolol | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Inc. | DR-XY35610 | Mar 18, 2029 | |
HypetorMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY43790 | Oct 16, 2029 | |
IdesorMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Medhaus Pharma, IncorporatedTrader: Interhealthcare Pharmaceuticals Inc. | DRP-1553-02 | May 5, 2029 | |
LoprexoMetoprolol tartrate | 100 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-12907 | Oct 27, 2027 | |
LoprexoMetoprolol Tartrate | 100 mg TabletAlu/PVC/ACLAR Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-10784 | Nov 18, 2026 | |
LoprexoMetoprolol tartrate | 50 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-12906 | Oct 27, 2027 | |
LoprexoMetoprolol Tartrate | 50 mg TabletAlu/PVC/ACLAR Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | CSPC Ouyi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-12168 | Jun 28, 2027 | |
M-CardMetoprolol tartrate | 1 mg/mL Solution for I.V. Injection5 mL (net content) USP Type I clear and colorless glass vial enclosed with dark gray Teflon-coated rubber closure and aluminum seal with blue plastic flip-off cap placed in a plastic tray (Box of 5's and 10's) | RxVAT-exempt | Baxter Pharmaceuticals India Private LimitedIndia | Baxter Healthcare Philippines, Inc. | DR-XY47881 | Mar 31, 2027 | |
Meobloc 100Metoprolol Tartrate | 100 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | A.T.C. Healthcare International Corp. | DRP-13314 | Jan 26, 2028 | |
Meobloc 50Metoprolol Tartrate | 50 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | Trader: A.T.C. Health Care International Corp. | DRP-12447 | Aug 9, 2027 | |
MeterolMetoprolol Tartrate | 100 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-16684 | Jun 5, 2030 | |
MeterolMetoprolol Tartrate | 50 mg TabletAlu Clear/PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-14561 | Oct 13, 2030 | |
MetocardMetoprolol Tartrate | 100 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-1765 | Jul 11, 2031 | |
MetocardMetoprolol tartrate | 50 mg Film-Coated Tablet | RxVAT-exempt | Lloyd Laboratories, Inc. | Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-4567 | Dec 19, 2026 | |
MetocareMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: IAE Pharmaceuticals Corp. | DRP-1764 | Jan 12, 2029 | |
MetocareMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: IAE Pharmaceuticals Corp. | DRP-1763 | Jan 12, 2029 | |
Metopar 100Metoprolol | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Alwin DMD PharmaceuticalsIndia | Aspar Pharmaceutical Inc. | DRP-17471 | Jan 6, 2031 | |
Metopar 50Metoprolol | 50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Alwin DMD PharmaceuticalsIndia | Aspar Pharmaceutical Inc. | DRP-17472 | Jan 6, 2031 | |
MetoprimMetoprolol Tartrate | 100 mg TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Primera Pharma, Corp. | DR-XY38922 | Jan 4, 2030 | |
MetorpimMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Primera Pharma, Corporation | DR-XY30344 | Jan 19, 2029 | |
Metosaph-100Metoprolol Tartrate | 100 mg TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. LtdIndia | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-1809-04 | Aug 25, 2027 | |
Metosaph-50Metoprolol Tartrate | 50 mg TabletAmber PVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. LtdIndia | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals Inc | DRP-1858-05 | Aug 15, 2027 | |
MetospecMetoprolol Tartrate | 50 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Pharmaspec N.A., Inc. | DR-XY19456-B | Sep 29, 2029 | |
MetostadMetoprolol Tartrate | 50mg TabletAlu/Clear PVC/PVDC Blister Pack x 10's Box of 50's and 100's | RxVAT-exempt | STADA Arzneimittel AGGermany | STADA Philippines Inc. | DRP-416 | Dec 5, 2027 | |
MetovascMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Transcend Phils., Inc. | DRP-8684 | Apr 13, 2030 | |
MetovinMetoprolol Tartrate | 100 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Vincare PharmaTrader: Eadriex Pharmaceuticals Phils., Inc. | DRP-1765-01 | Jul 11, 2031 | |
MetozanMetoprolol Tartrate | 50 mg TabletAlu Clear/PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-14561-01 | Oct 13, 2030 | |
MetrololMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1553-08 | May 5, 2029 | |
MyprolMetoprolol Tartrate | 50 mg TabletAlu/Orange PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | New Myrex Laboratories, Inc.Philippines | — | DRP-9036 | Aug 6, 2031 | |
Neo-HartMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Vitalink Health Products, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1554-03 | Mar 30, 2029 | |
NeoblocMetoprolol Tartrate | 100 mg TabletPVDC White/Alu Blister Pack x 10's (Box of 100's); PVDC White/Alu Blister Pack x 10's (Box of 500's) | RxVAT-exempt | HIZON LABORATORIES, INC.Philippines | Trader: GX INTERNATIONAL, INC. | DR-XY27498 | Oct 3, 2028 | |
NeoblocMetoprolol Tartrate | 50 mg TabletPVDC White Alu/Blister Pack x 10's (Box of 100's); PVDC White Alu/Blister Pack x 10's (Box of 500's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY27497 | Oct 3, 2028 | |
Neox 50Metoprolol Tartrate | 50 mg Film-Coated TabletClear PVDC / Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY36008 | Jun 19, 2029 | |
Neox ERMetoprolol Succinate | 95 mg Extended Release Tablet (equivalent to 100 mg Metoprolol tartrate)Aluminum Foil Strip x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY40679 | Feb 23, 2027 | |
NoneMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY44260 | Mar 19, 2030 | |
NoneMetoprolol (as tartrate) | 100 mg Film-Coated TabletAlu/AWhite PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-11760 | Apr 13, 2030 | |
NoneMetoprolol Tartrate | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Gamot Philippines, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1554-09 | Mar 30, 2029 | |
NoneMetoprolol Tartrate | 100 mg TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: RITEMED PHILS., INC. | DRP-2846 | Jan 11, 2028 | |
NoneMetoprolol Tartrate | 100 mg TabletAluminum Foil Strip x l0's Box of 100's | RxVAT-exempt | Pascual Laboratories, Inc.Philippines | — | DRP-5093 | Oct 18, 2030 | |
NoneMetoprolol Tartrate | 100 mg TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Watsons Personal Care Stores (Philippines), Inc. | DRP-5093-01 | Sep 19, 2031 | |
NoneMetoprolol tartrate | 50 mg Film-Coated TabletAlu-Clear PVDC Blister Pack x 10's (Box of 60's) - DOH Complete Treatment Pack | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Westfield Pharmaceuticals, Inc.Trader: Vitalink Health Products, Inc. | DR-XY43690 (For DOH Only) | Aug 27, 2030 | |
NoneMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY44261 | Apr 28, 2030 | |
NoneMetoprolol tartrate | 50 mg Film-Coated TabletAlu / PVC Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Qualifirst Health Inc.Importer: AMB HK Enterprises Inc. | DRP-12906-01 | Oct 27, 2027 | |
NoneMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-7133 | Apr 13, 2030 | |
NoneMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | St. Joseph DrugstoreTrader: Innogen Pharmaceuticals, Inc. | DRP-7133-01 | Apr 13, 2030 | |
NoneMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | South Star DrugTrader: Innogen Pharmaceuticals, Inc. | DRP-7133-02 | Apr 13, 2030 | |
NoneMetoprolol Tartrate | 50 mg TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: RITEMED PHILS., INC. | DRP-2887 | Jan 7, 2028 | |
NoneMetoprolol Tartrate | 50 mg TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Watsons Personal Care Stores (Philippines), Inc. | DRP-5097-01 | Oct 10, 2031 | |
NoneMetoprolol Tartrate | 50 mg TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Rose Pharmacy, Incorporated | DRP-5097-02 | Oct 9, 2031 | |
NoneMetoprolol Tartrate | 50 mg TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma, Inc. | DRP-800-02 | Mar 22, 2028 | |
Ometpro-100Metoprolol Succinate (equivalent to 100 mg Metoprolol Tartrate) | 95 mg Extended-Release TabletAluminum Foil Strip x 10 tablets (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY40826 | Apr 16, 2027 | |
PololMetoprolol Tartrate | 100 mg TabletAlu / PVC Clear Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16684-01 | Jun 5, 2030 | |
POLOLMetoprolol Tartrate | 50 mg TabletAlu Clear/PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-14561-02 | Oct 13, 2030 | |
PrincicarMetoprolol Tartrate | 100 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-3872 | Nov 19, 2029 | |
PrincicarMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-10729 | Mar 19, 2030 | |
ProlatMetoprolol (as tartrate) | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | WeCare Pharma Corp.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1553-09 | May 5, 2029 | |
ProledMetoprolol Tartrate | 50 mg TabletAlu/Green-colored PVC Blister x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | 777 Red Pharma IncImporter: Nelpa Lifesciences, Inc. | DRP-5883-01 | Mar 4, 2031 | |
ProlohexMetoprolol Tartrate | 100mg TabletBlister pack x 10's (Box of 100's) | RxVAT-exempt | Salutas Pharma GmbHGermany | Importer: Sandoz Philippines Corporation | DRP-1192 | Aug 12, 2027 | |
PrololMetoprolol Tartrate | 100 mg TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Health Saver Pharma Inc. | DRP 1809 | Aug 25, 2027 | |
PrololMetoprolol Tartrate | 100 mg TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-1809 | Aug 25, 2027 | |
PrololMetoprolol Tartrate | 50 mg TabletAmber PVC/Alu Blister Pack x 10's (Box of 100's); Amber PVC/Alu Blister Pack x 10's (Box of 60's) for DOH Complete Treatment Pack (DOH Project Only) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Health Saver Pharma Inc. | DRP 1858 | Aug 15, 2027 | |
PrololMetoprolol Tartrate | 50 mg TabletAmber PVC/Alu Blister Pack x 10's (Box of 100's); Amber PVC/Alu Blister Pack x 10's (Box of 60's) for DOH Complete Treatment Pack (DOH Project Only) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-1858 | Aug 15, 2027 | |
PrometinMetoprolol Tartrate | 50 mg TabletAlu/Green-colored PVC Blister x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-5883 | Mar 4, 2031 | |
Prometin-100Metoprolol Tartrate | 100mg TabletAlu/Green PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-10917 | Dec 17, 2026 | |
Regitol 100Metoprolol Tartrate | 100 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Bulacan | Regimed Pharmaceutical Distributor | DRP-16684-03 | Jun 5, 2030 | |
Regitol 50Metoprolol Tartrate | 50 mg TabletAlu Clear/PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-14561-04 | Oct 13, 2030 | |
RetablocMetoprolol Tartrate | 50 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Reta DrugTrader: Vitalink Health Products, Inc. | DRP-3073-03 | Sep 30, 2028 | |
RezeblocMetoprolol tartrate | 50mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | I.E. Medica, Inc. | DRP-9056 | Oct 20, 2030 | |
Saphorolol-100Metoprolol Tartrate | 100mg TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-18445 | Jul 13, 2031 | |
SydenmetMetoprolol Tartrate | 100 mg TabletFoil Strip x 10's Box of 100's | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-627 | Nov 2, 2029 | |
UnbrandedMetoprolol Tartrate | 100 mg TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Rose Pharmacy, Incorporated | DRP-5093-02 | Oct 26, 2037 | |
UnbrandedMetoprolol Tartrate | 50 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Gamot Philippines, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1553-10 | May 5, 2029 | |
UnbrandedMetoprolol tartrate | 50mg TabletAluminum Foil Strip x 10's Box of 100's | RxVAT-exempt | Pascual Laboratories, Inc.Philippines | — | DRP-5097 | Oct 18, 2030 | |
UnbrandedMetoprolol tartrate | 50mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | I.E. Medica, Inc. | DRP-9057 | Aug 20, 2030 | |
UnbrandedMetoprolol tartrate | 50mg TabletAlu/Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Actimed, Inc.Importer: I.E. Medica, Inc. | DRP-9059 | Oct 20, 2030 | |
ZionelMetoprolol (as tartrate) | 100 mg Film-Coated TabletClear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-4215 | Nov 23, 2029 | |
ZionelMetoprolol Tartrate | 50 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-3073 | Sep 30, 2028 | |
(no brand name)Metoprolol Tartrate | 100 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | — | DRP-13313 | Jan 26, 2028 | |
(no brand name)Metoprolol tartrate | 100 mg TabletAlu/Alu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Am-Europharma Corporation.Philippines | Ritemed Phils., Inc. | DRP-17021 | Sep 8, 2030 | |
(no brand name)Metoprolol Tartrate | 50 mg TabletAlu/Opaque White PVC Film Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | Phil. United Pharma CorporationPhilippines | — | DRP-12446 | Aug 9, 2027 | |
(no brand name)Metoprolol tartrate | 50 mg TabletAlu/Alu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Am-Europharma CorporationPhilippines | Ritemed Phils., Inc. | DRP-17022 | Sep 8, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS LOPRESSOR is supplied as: 50 mg tablet – capsule shaped, biconvex, pink, scored (imprinted GEIGY on one side and 51 twice on the scored side) 100 mg tablet – capsule shaped, biconvex, light blue, scored (imprinted with GEIGY on one side and 71 twice on the scored side) LOPRESSOR (metoprolol tartrate) tablets: 50 mg and 100 mg. (3)
Warnings/Precautions
- Abrupt cessation may exacerbate myocardial ischemia. (5.1)
- Heart Failure: Worsening cardiac failure may occur. (5.2)
- Bronchospastic Disease: Avoid beta-blockers. (5.3)
- Pheochromocytoma: Initiate therapy with an alpha blocker. (5.4)
- Major Surgery: Avoid initiation of high-dose extended-release metoprolol in patients undergoing non-cardiac surgery. Do not routinely withdraw chronic beta-blocker therapy prior to surgery. (5.5, 6.1)
- Diabetes: May mask symptoms of hypoglycemia. (5.6)
- Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. (5.7)
- Peripheral Vascular Disease: Can aggravate symptoms of arterial insufficiency. (5.9)
5.1 Abrupt Cessation of Therapy
5.1 Abrupt Cessation of Therapy Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered LOPRESSOR, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of 1 to 2 weeks and monitor the patient.
If angina markedly worsens or acute coronary ischemia develops, promptly reinstate LOPRESSOR, and take measures appropriate for the management of unstable angina. Warn patients not to interrupt therapy without their physician’s advice. Because coronary artery disease is common and may be unrecognized, avoid abruptly discontinuing LOPRESSOR in patients treated only for hypertension.
5.2 Heart Failure
5.2 Heart Failure Worsening cardiac failure may occur during up-titration of LOPRESSOR. If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of LOPRESSOR [see Dosage and Administration (2)]. It may be necessary to lower the dose of LOPRESSOR or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of LOPRESSOR.
5.3 Bronchospastic Disease
5.3 Bronchospastic Disease Patients with bronchospastic disease, should in general, not receive beta-blockers, including Lopressor. Because of its relative beta 1 cardio-selectivity, however, LOPRESSOR may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment.
Because beta 1 -selectivity is not absolute, use the lowest possible dose of LOPRESSOR. Bronchodilators, including beta 2 -agonists, should be readily available or administered concomitantly [see Dosage and Administration (2)].
5.4 Pheochromocytoma If
5.4 Pheochromocytoma If LOPRESSOR is used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.
5.5 Major Surgery
5.5 Major Surgery Avoid initiation of a high-dose regimen of beta-blocker therapy in patients undergoing non-cardiac surgery, since such use in patients with cardiovascular risk factors has been associated with bradycardia, hypotension, stroke and death. Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.
5.6 Hypoglycemia
5.6 Hypoglycemia Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting). If severe hypoglycemia occurs, patients should be instructed to seek emergency treatment.
Beta-blockers may ask some of the manifestations of hypoglycemia, particularly tachycardia. 5. 7 Thyrotoxicosis Beta-adrenergic blockade may mask certain clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockade may precipitate a thyroid storm.
5.8 Risk of Anaphylactic Reactions
5.8 Risk of Anaphylactic Reactions While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. 5. 9 Peripheral Vascular Disease Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.
Drug interactions
- Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. (7.1)
- Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (7.2)
- CYP2D6 Inhibitors are likely to increase metoprolol concentration. (7.3)
- Concomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase the risk of bradycardia. (7.4)
- Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. (7.4)
7.1 Catecholamine Depleting Drugs
7.1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with LOPRESSOR plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
7.2 Epinephrine
7.2 Epinephrine While taking beta-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated challenge and may be unresponsive to the usual doses of epinephrine used to treat an allergic reaction.
7.3 CYP2D6 Inhibitors
7.3 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to increase metoprolol concentration. Increases in plasma concentration decrease the cardioselectivity of metoprolol [see Clinical Pharmacology (12.3)].
Monitor patients closely, when the combination cannot be avoided. 7. 4 Negative Chronotropes Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. Concomitant use with beta-blockers can increase the risk of bradycardia. If clonidine and a beta-blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine.
If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metoprolol is not a significant P-glycoprotein substrate.
The mean elimination half-life of metoprolol is 3 to 4 hours; in poor CYP2D6 metabolizers the half-life may be 7 to 9 hours.
Metabolism: Lopressor is primarily metabolized by CYP2D6.
CYP2D6 is absent (poor metabolizers) in about 8% of Caucasians and about 2% of most other populations.
Poor CYP2D6 metabolizers exhibit several-fold higher plasma concentrations of Lopressor than extensive metabolizers with normal CYP2D6 activity thereby decreasing Lopressor’s cardioselectivity.
Drug Interactions Metoprolol is metabolized predominantly by CYP2D6.
In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg, a potent CYP2D6 inhibitor, and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life.
Extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions ( 7.2 )] .
Adverse reactions
- The following adverse reactions are described elsewhere in labeling: Worsening angina or myocardial infarction [see Warnings and Precautions (5)] Worsening heart failure [see Warnings and Precautions (5)]. Worsening AV block [see Contraindications (4)]. Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Validus Pharmaceuticals LLC at 1-866-982-5438 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypertension and Angina Most adverse effects have been mild and transient.
Central Nervous System: Tiredness and dizziness have occurred in about 10% of patients. Depression has been reported in about 5 of 100 patients. Mental confusion and short-term memory loss have been reported. Headache, nightmares, and insomnia have also been reported. Cardiovascular: Shortness of breath and bradycardia have occurred in approximately 3% of patients.
Cold extremities; arterial insufficiency, usually of the Raynaud type; palpitations; heart failure exacerbations; peripheral edema; and hypotension have been reported in about 1% of patients. Gangrene in patients with pre-existing severe peripheral circulatory disorders has also been reported. [see Contraindications (4) and Warnings and Precautions (5.2)].
Respiratory: Wheezing (bronchospasm) and dyspnea have been reported in about 1% of patients [see Warnings and Precautions (5.3)]. Rhinitis has also been reported. Gastrointestinal: Diarrhea has occurred in about 5% of patients. Nausea, dry mouth, gastric pain, constipation, flatulence, and heartburn have been reported in about 1% of patients.
Vomiting was a common occurrence. Hypersensitive Reactions: Pruritus or rash have occurred in about 5% of patients. Photosensitivity and worsening of psoriasis has been reported. Miscellaneous: Peyronie’s disease, musculoskeletal pain, blurred vision, and tinnitus has been reported. Myocardial Infarction In general, the adverse reactions observed in trials with metoprolol in MI are consistent with the hypertension and angina experience.
In a randomized comparison of Lopressor and placebo in the setting of acute MI the following adverse reactions were reported: Lopressor ® Placebo Hypotension (systolic BP < 90 mm Hg) 27.4% 23.2% Bradycardia (heart rate < 40 beats/min) 15.9% 6.7% Second- or third-degree heart block 4.7% 4.7% First-degree heart block (P-R ≥ 0.26 sec) 5.3% 1.9% Heart failure 27.5% 29.6%
6.2 Post-Marketing Experience
6.2 Post-Marketing Experience The following adverse reactions have been identified during post approval use of LOPRESSOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Central Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. Cardiovascular: Intensification of AV block [see Contraindications (4)].
Hematologic: Agranulocytosis, nonthrombocytopenic purpura and thrombocytopenic purpura. Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm and respiratory distress. Laboratory Findings: Increase in blood triglycerides, elevated transaminase and decrease in High Density Lipoprotein (HDL)
Adverse reaction frequency tables (US label) US FDA label
| Lopressor® | Placebo | |
| Hypotension (systolic BP < 90 mm Hg) | 27.4% | 23.2% |
| Bradycardia (heart rate < 40 beats/min) | 15.9% | 6.7% |
| Second- or third-degree heart block | 4.7% | 4.7% |
| First-degree heart block (P-R ≥ 0.26 sec) | 5.3% | 1.9% |
| Heart failure | 27.5% | 29.6% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published observational studies have not demonstrated an association of adverse developmental outcomes with maternal use of metoprolol during pregnancy (see Data). Untreated hypertension and myocardial infarction during pregnancy can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations).
In animal reproduction studies, metoprolol has been shown to increase post-implantation loss and decrease neonatal survival in rats at oral dosages of 500 mg/kg/day, approximately 11 times the daily dose of 450 mg in a 60-kg patient on a mg/m 2 basis. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical consideration Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).
Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Metoprolol crosses the placenta. Neonates born to mothers who are receiving metoprolol during pregnancy, may be at risk for hypotension, hypoglycemia, bradycardia, and respiratory depression.
Observe neonates and manage accordingly. Data Human Data Data from published observational studies did not demonstrate an association of major congenital malformations and use of metoprolol in pregnancy. The published literature has reported inconsistent findings of intrauterine growth retardation, preterm birth and perinatal mortality with maternal use of metoprolol during pregnancy; however, these studies have methodological limitations hindering interpretation.
Methodological limitations include retrospective design, concomitant use of other medications, and other unadjusted confounders that may account for the study findings including the underlying disease in the mother. These observational studies cannot definitely establish or exclude any drug-associated risk during pregnancy.
Animal Data Metoprolol has been shown to increase post-implantation loss and decrease neonatal survival in rats at oral dosages of 500 mg/kg/day, i.e., 11 times, on a mg/m 2 basis, the daily dose of 450 mg in a 60-kg patient. No fetal abnormalities were observed when pregnant rats received metoprolol orally up to a dose of 200 mg/kg/day, i.e., 4 times, the daily dose of 400mg in a 60-kg patient.
Mechanism of action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade.
Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1 -selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta 2 -mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine.
(2) In asthmatic patients, metoprolol reduces FEV 1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta 1 -receptor blocking doses. Hypertension: The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output; (2) a central effect leading to reduced sympathetic outflow to the periphery; and (3) suppression of renin activity.
Angina Pectoris: By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements of the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris. Heart Failure: The precise mechanism for the beneficial effects of beta-blockers in heart failure has not been elucidated.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation.
Beta 1 -blocking effects in the range of 30-80% of the maximal effect (approximately 8 to 23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30 to 540 nmol/L. The relative beta 1 -selectivity of metoprolol diminishes and blockade of beta 2 -adrenoceptors increases at plasma concentration above 300 nmol/L.
Significant beta-blocking effect (as measured by reduction of exercise heart rate) occurs within 1 hour after oral administration, and its duration is dose-related. For example, a 50% reduction of the maximum effect after single oral doses of 20, 50, and 100 mg occurred at 3.3, 5.0, and 6.4 hours, respectively, in normal subjects.
After repeated oral dosages of 100 mg twice daily, a significant reduction in exercise systolic blood pressure was evident at 12 hours. When the drug was infused over a 10-minute period, in normal volunteers, maximum beta-blockade was achieved at approximately 20 minutes. Equivalent maximal beta-blocking effect is achieved with oral and intravenous doses in the ratio of approximately 2.5:1.
There is a linear relationship between the log of plasma levels and reduction of exercise heart rate. However, antihypertensive activity does not appear to be related to plasma levels. Because of variable plasma levels attained with a given dose and lack of a consistent relationship of antihypertensive activity to dose, selection of proper dosage requires individual titration.
In several studies of patients with acute myocardial infarction, intravenous followed by oral administration of Lopressor caused a reduction in heart rate, systolic blood pressure and cardiac output. Stroke volume, diastolic blood pressure and pulmonary artery end diastolic pressure remained unchanged.
Pharmacokinetics
The mean elimination half-life of metoprolol is 3 to 4 hours; in poor CYP2D6 metabolizers the half-life may be 7 to 9 hours.
Excretion Approximately 95% of the dose can be recovered in urine.
In most subjects (extensive metabolizers), less than 5% of an oral dose and less than 10% of an intravenous dose are excreted as unchanged drug in the urine.
In poor metabolizers, up to 30% or 40% of oral or intravenous doses, respectively, may be excreted unchanged; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.
The renal clearance of the stereo-isomers does not exhibit stereo-selectivity in renal excretion.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption: The estimated oral bioavailability of immediate release metoprolol is about 50% because of pre-systemic metabolism which is saturable leading to non-proportionate increase in the exposure with increased dose. Distribution: Metoprolol is extensively distributed with a reported volume of distribution of 3.2 to 5.6 L/kg.
About 10% of metoprolol in plasma is bound to serum albumin. Metoprolol is known to cross the placenta and is found in breast milk. Metoprolol is also known to cross the blood brain barrier following oral administration and CSF concentrations close to that observed in plasma have been reported. Metoprolol is not a significant P-glycoprotein substrate.
Elimination: Elimination of Lopressor is mainly by biotransformation in the liver. The mean elimination half-life of metoprolol is 3 to 4 hours; in poor CYP2D6 metabolizers the half-life may be 7 to 9 hours. Metabolism: Lopressor is primarily metabolized by CYP2D6. Metoprolol is a racemic mixture of R- and S- enantiomers, and when administered orally, it exhibits stereoselective metabolism that is dependent on oxidation phenotype.
CYP2D6 is absent (poor metabolizers) in about 8% of Caucasians and about 2% of most other populations. Poor CYP2D6 metabolizers exhibit several-fold higher plasma concentrations of Lopressor than extensive metabolizers with normal CYP2D6 activity thereby decreasing Lopressor’s cardioselectivity. Excretion Approximately 95% of the dose can be recovered in urine.
In most subjects (extensive metabolizers), less than 5% of an oral dose and less than 10% of an intravenous dose are excreted as unchanged drug in the urine. In poor metabolizers, up to 30% or 40% of oral or intravenous doses, respectively, may be excreted unchanged; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.
The renal clearance of the stereo-isomers does not exhibit stereo-selectivity in renal excretion. Specific populations Geriatric patients: The geriatric population may show slightly higher plasma concentrations of metoprolol as a combined result of a decreased metabolism of the drug in elderly population and a decreased hepatic blood flow.
However, this increase is not clinically significant or therapeutically relevant. Renal impairment: The systemic availability and half-life of Lopressor in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. Hepatic Impairment: Since the drug is primarily eliminated by hepatic metabolism, hepatic impairment may impact the pharmacokinetics of metoprolol.
Drug Interactions Metoprolol is metabolized predominantly by CYP2D6. In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg, a potent CYP2D6 inhibitor, and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life.
In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. increased the steady-state metoprolol concentration 2- to 5-fold compared to metoprolol alone. Extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Metoprolol (as Tartrate) 50 mg Tablet | ₱0.46–₱3.65Reference ₱0.95 | per tablet | DPRI procurement range |
| Metoprolol (as Tartrate) 100 mg Tablet | ₱0.83–₱4.85Reference ₱1.55 | per tablet | DPRI procurement range |
| 50 mg (as tartrate) tablet | ₱2.25 | per tablet | PhilHealth GAMOT fixed fee |
| 100 mg (as tartrate) tablet | ₱3.50 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Metoprolol (as tartrate) |
| PNF listing | Oral: 50 mg and 100 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Lopressor · Validus Pharmaceuticals LLC [US FDA-approved label, version 10, September 14, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0283bc9d-6998-493a-824a-d4c85f704111
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
